The effect of oleoylethanolamide supplementation on serum levels of inflammatory factors (IL-1β, hs-CRP, TNF-α, MCP-1) in adult patients with non-alcoholic fatty liver disease: A triple-blinded, randomized, placebo-controlled clinical trial

Abstract

Non-alcoholic fatty liver disease (NAFLD) is recognized as the most frequent chronic liver malady globally. Oxidative stress is regarded as the leading cause of various liver diseases. This trial investigated the effects of oleoylethanolamide (OEA) administration on inflammatory markers of adult obese patients with NAFLD. Materials and Methods: The present randomized placebo‐controlled clinical trial was conducted on 60 obese patients with NAFLD. The patients were treated with OEA (250 mg/day) or placebo along with a low-calorie diet for 12 weeks. Anthropometric measurements, dietary intakes, inflammatory markers, and oxidative stress and antioxidant parameters were evaluated pre-and post-intervention. Results: At the end of the study, a significant decrease in weight, body mass index, and energy intake were observed in the OEA group compared to the placebo group (p<0.05). In evaluating the values of hs-CRP, MCP-1, IL-1B and TNF-a variables, no significant statistical difference was observed between the two groups and within each group.